Fernando Docobo-PÃ©rez

List of Publications by Year
in descending order

53 papers	1,619 citations	236612 25 h-index	301761 39 g-index
53 all docs	53 docs citations	53 times ranked	2273 citing authors

#	Article	IF	Citations
1	Impaired Virulence and In Vivo Fitness of Colistin-Resistant Acinetobacter baumannii. Journal of Infectious Diseases, 2011, 203, 545-548.	1.9	138
2	Vaccination with Outer Membrane Complexes Elicits Rapid Protective Immunity to Multidrug-Resistant Acinetobacter baumannii. Infection and Immunity, 2011, 79, 518-526.	1.0	116
3	Efficacy of Rifampin and Its Combinations with Imipenem, Sulbactam, and Colistin in Experimental Models of Infection Caused by Imipenem-Resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2010, 54, 1165-1172.	1.4	109
4	Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance. Antimicrobial Agents and Chemotherapy, 2015, 59, 5602-5610.	1.4	87
5	Interplay between plasmid-mediated and chromosomal-mediated fluoroquinolone resistance and bacterial fitness in Escherichia coli. Journal of Antimicrobial Chemotherapy, 2014, 69, 3203-3215.	1.3	76
6	Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum Î²-lactamase-producing and extended-spectrum Î²-lactamase-non-producing Escherichia coli isolates.. Clinical Microbiology and Infection, 2010, 16, 132-136.	2.8	71
7	Quinolone Resistance Reversion by Targeting the SOS Response. MBio, 2017, 8, .	1.8	54
8	Platelet-activating Factor Receptor Initiates Contact of Acinetobacter baumannii Expressing Phosphorylcholine with Host Cells. Journal of Biological Chemistry, 2012, 287, 26901-26910.	1.6	53
9	Inoculum Effect on the Efficacies of Amoxicillin-Clavulanate, Piperacillin-Tazobactam, and Imipenem against Extended-Spectrum Î²-Lactamase (ESBL)-Producing and Non-ESBL-Producing Escherichia coli in an Experimental Murine Sepsis Model. Antimicrobial Agents and Chemotherapy, 2013, 57, 2109-2113.	1.4	51
10	Studies on the antimicrobial activity of cecropin A-melittin hybrid peptides in colistin-resistant clinical isolates of Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy, 2006, 58, 95-100.	1.3	50
11	Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli. International Journal of Antimicrobial Agents, 2012, 39, 251-254.	1.1	50
12	Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam. Journal of Antimicrobial Chemotherapy, 2006, 58, 689-692.	1.3	45
13	Impact of AAC(6â€²)-Ib-cr in combination with chromosomal-mediated mechanisms on clinical quinolone resistance inEscherichia coli. Journal of Antimicrobial Chemotherapy, 2016, 71, 3066-3071.	1.3	39
14	Efficacy of Daptomycin versus Vancomycin in an Experimental Model of Foreign-Body and Systemic Infection Caused by Biofilm Producers and Methicillin-Resistant Staphylococcus epidermidis. Antimicrobial Agents and Chemotherapy, 2012, 56, 613-617.	1.4	38
15	Role of inoculum and mutant frequency on fosfomycin MIC discrepancies by agar dilution and broth microdilution methods in Enterobacteriaceae. Clinical Microbiology and Infection, 2017, 23, 325-331.	2.8	38
16	Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates. Journal of Antimicrobial Chemotherapy, 2016, 71, 992-1002.	1.3	37
17	Acinetobacter baumannii-induced lung cell death: Role of inflammation, oxidative stress and cytosolic calcium. Microbial Pathogenesis, 2011, 50, 224-232.	1.3	36
18	Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1. Clinical Microbiology and Infection, 2008, 14, 691-697.	2.8	33

#	Article	IF	Citations
19	Attenuated virulence of a slow-growing pandrug-resistant Acinetobacter baumannii is associated with decreased expression of genes encoding the porins CarO and OprD-like. International Journal of Antimicrobial Agents, 2011, 38, 548-549.	1.1	31
20	Impact of qnrA1, qnrB1 and qnrS1 on the efficacy of ciprofloxacin and levofloxacin in an experimental pneumonia model caused by Escherichia coli with or without the GyrA mutation Ser83Leu. Journal of Antimicrobial Chemotherapy, 2013, 68, 1609-1615.	1.3	29
21	Population Pharmacokinetics of Teicoplanin in Children. Antimicrobial Agents and Chemotherapy, 2014, 58, 6920-6927.	1.4	29
22	Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy. Antimicrobial Agents and Chemotherapy, 2016, 60, 2336-2342.	1.4	29
23	Molecular insights into fosfomycin resistance inEscherichia coli. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw573.	1.3	29
24	Efficacy of cecropin A-melittin peptides on a sepsis model of infection by pan-resistant Acinetobacter baumannii. European Journal of Clinical Microbiology and Infectious Diseases, 2011, 30, 1391-1398.	1.3	26
25	In vitro and in vivo reduced fitness and virulence in ciprofloxacin-resistant Acinetobacter baumannii. Clinical Microbiology and Infection, 2012, 18, E1-E4.	2.8	26
26	Efficacy of linezolid versus a pharmacodynamically optimized vancomycin therapy in an experimental pneumonia model caused by methicillin-resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy, 2012, 67, 1961-1967.	1.3	25
27	Efficacy of tigecycline vs. imipenem in the treatment of experimental Acinetobacter baumannii murine pneumonia. European Journal of Clinical Microbiology and Infectious Diseases, 2010, 29, 527-531.	1.3	24
28	Clinical Relevance and Prevalence of Polymorphisms in CYP3A5 and MDR1 Genes That Encode Tacrolimus Biotransformation Enzymes in Liver Transplant Recipients. Transplantation Proceedings, 2008, 40, 2949-2951.	0.3	22
29	Urinary Tract Conditions Affect Fosfomycin Activity against Escherichia coli Strains Harboring Chromosomal Mutations Involved in Fosfomycin Uptake. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	22
30	Efficacy of rifampin, in monotherapy and in combinations, in an experimental murine pneumonia model caused by panresistant Acinetobacter baumannii strains. European Journal of Clinical Microbiology and Infectious Diseases, 2011, 30, 895-901.	1.3	20
31	Population pharmacokinetics and pharmacodynamics of fosfomycin in nonâ€“critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli. Clinical Microbiology and Infection, 2018, 24, 1177-1183.	2.8	18
32	Molecular Screening ofBartonellaSpecies in Rodents from South Western Spain. Vector-Borne and Zoonotic Diseases, 2008, 8, 695-700.	0.6	17
33	Suppression of the SOS response modifies spatiotemporal evolution, post-antibiotic effect, bacterial fitness and biofilm formation in quinolone-resistant Escherichia coli. Journal of Antimicrobial Chemotherapy, 2019, 74, 66-73.	1.3	17
34	Genotypic diversity of imipenem resistant isolates of Acinetobacter baumannii in Spain. Journal of Infection, 2007, 55, 260-266.	1.7	16
35	Molecular Epidemiology of HIV Type 1 in Newly Diagnosed Patients in Southern Spain. AIDS Research and Human Retroviruses, 2008, 24, 881-887.	0.5	12
36	Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance. Antimicrobial Agents and Chemotherapy, 2021, 65, e0029321.	1.4	12

#	Article	IF	Citations
37	Pre-clinical studies of a new quinolone (UB-8902) against Acinetobacter baumannii resistant to ciprofloxacin. International Journal of Antimicrobial Agents, 2011, 38, 355-359.	1.1	10
38	In Vitro Activity and In Vivo Efficacy of Clavulanic Acid against Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2009, 53, 4298-4304.	1.4	9
39	Emergence of OXA-72-producing Acinetobacter pittii clinical isolates. International Journal of Antimicrobial Agents, 2014, 43, 195-196.	1.1	9
40	Role of low-level quinolone resistance in generating tolerance in Escherichia coli under therapeutic concentrations of ciprofloxacin. Journal of Antimicrobial Chemotherapy, 2020, 75, 2124-2132.	1.3	9
41	Synergistic Quinolone Sensitization by Targeting the recA SOS Response Gene and Oxidative Stress. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	8
42	Detection of Low-Level Fosfomycin-Resistant Variants by Decreasing Glucose-6-Phosphate Concentration in Fosfomycin Susceptibility Determination. Antibiotics, 2020, 9, 802.	1.5	7
43	Effect of RecA inactivation on quinolone susceptibility and the evolution of resistance in clinical isolates of Escherichia coli. Journal of Antimicrobial Chemotherapy, 2021, 76, 338-344.	1.3	7
44	Interplay among Different Fosfomycin Resistance Mechanisms in Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	7
45	Contribution of hypermutation to fosfomycin heteroresistance in Escherichia coli. Journal of Antimicrobial Chemotherapy, 2020, 75, 2066-2075.	1.3	6
46	Effect of RecA inactivation and detoxification systems on the evolution of ciprofloxacin resistance in Escherichia coli. Journal of Antimicrobial Chemotherapy, 2022, 77, 641-645.	1.3	5
47	Efficacy of Î²-lactams against experimental pneumococcal endocarditis caused by strains with different susceptibilities to penicillin. Journal of Antimicrobial Chemotherapy, 2005, 56, 732-737.	1.3	3
48	Efficacy of amoxycillinâ€“clavulanate in an experimental model of murine pneumonia caused by AmpC-non-hyperproducing clinical isolates of Escherichia coli resistant to cefoxitin. Clinical Microbiology and Infection, 2008, 14, 582-587.	2.8	3
49	Local imipenem activity against Pseudomonas aeruginosa decreases in vivo in the presence of siliconized latex. European Journal of Clinical Microbiology and Infectious Diseases, 2011, 30, 289-291.	1.3	3
50	Population Pharmacokinetics of Piperacillin in Non-Critically Ill Patients with Bacteremia Caused by Enterobacteriaceae. Antibiotics, 2021, 10, 348.	1.5	3
51	Activity of Fosfomycin and Amikacin against Fosfomycin-Heteroresistant Escherichia coli Strains in a Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	3
52	Disbalancing Envelope Stress Responses as a Strategy for Sensitization of Escherichia coli to Antimicrobial Agents. Frontiers in Microbiology, 2021, 12, 653479.	1.5	1
53	Role of inorganic phosphate concentrations in inÂvitro activity of fosfomycin. Clinical Microbiology and Infection, 2022, 28, 302.e1-302.e4.	2.8	1